A new study has found that many of Israel’s scientific institutions are not taking Zika seriously, and are instead focusing on ways to prevent the spread of the virus, such as by encouraging the development of vaccines and more efficient health care.
According to the new study published in the journal PLOS ONE, an estimated 15 percent of Israelis work in areas related to the Zika outbreak, but only 5 percent of the country’s scientists have actually sought treatment for Zika.
In fact, the researchers found that the majority of the scientists in Israel’s research and development departments have no interest in studying the Zika vaccine.
According the study, one reason for this is that the Israeli government has been slow to invest in research on the Zika crisis.
In the years following the outbreak, the country has been dealing with a significant number of cases, and it is estimated that an estimated 100,000 people were infected.
The country is still battling a number of outbreaks in its hospitals, and many hospitals have been overwhelmed.
Despite the lack of funding, the Israeli public has become increasingly interested in research in the vaccine.
The new study suggests that a substantial number of scientists are interested in studying how to improve the vaccine, especially in the areas of efficiency and safety.
The researchers surveyed the scientific leadership in the country and found that only 4 percent of them had actually sought care for Zika, and only about one-third of them said they have sought treatment.
Among those who had sought treatment, a high percentage of them were women, and the average age was just over 50.
Researchers from the Max Planck Institute for Immunology in Frankfurt, Germany, and from the Hebrew University of Jerusalem said that these findings suggest that the lack-of-treatment rate among scientists in the field of Zika is due to a lack of knowledge about the disease and a reluctance to seek help.
“We can see that the reluctance to receive care may be a result of a fear of being stigmatized and stigmatized, and to avoid being accused of being in a lab,” Dr. Eran Ben-David said in a statement.
The Israeli researchers also found that among scientists who were not involved in Zika research, more than half of them have been reluctant to seek treatment, and that many have been afraid to seek care because they believe it will be too risky.
“This fear is probably because of the stigma attached to Zika, which makes it a risky disease,” Ben-Adeli said.